Demographic, clinical, and vaccination response data for participants grouped based on the vaccination scheme
| Variable . | Vector based, n = 28∗ . | Only 1†, n = 25∗ . | 2× mRNA-based, n = 168∗ . | P value‡ . |
|---|---|---|---|---|
| Age (y) | 53 (45; 60) | 55 (48; 61) | 60 (47; 69) | .05 |
| Sex | .2 | |||
| Female | 13 (46%) | 8 (32%) | 87 (52%) | |
| Male | 15 (54%) | 17 (68%) | 81 (48%) | |
| WBC | 5.5 (4.5; 6.1) | 5.7 (4.7; 7.1) | 6.3 (4.8; 8.2) | .1 |
| Study cohort | .07 | |||
| Healthy control | 13 (46%) | 16 (64%) | 62 (37%) | |
| Lymphoid neoplasms | 4 (14%) | 1 (4%) | 37 (22%) | |
| Myeloid neoplasms | 11 (39%) | 8 (32%) | 69 (41%) | |
| Prior SARS-CoV-2 infection | < .001 | |||
| Yes | 0 (0%) | 7 (28%) | 2 (1.2%) | |
| No | 28 (100%) | 18 (72%) | 166 (98.8%) | |
| Current cancer treatment | .4 | |||
| Yes | 11 (39%) | 6 (24%) | 64 (38%) | |
| No | 17 (61%) | 19 (76%) | 104 (62%) | |
| Spike-specific IgG detectable (n [%] of participants) | 26 (93%) | 23 (96%) | 159 (95%) | .9 |
| Spike-specific CD4+ T cells detectable (n [%] of participants) | 27 (96%) | 15 (60%) | 102 (61%) | .001 |
| Spike-specific CD8+ T cells detectable (n (%) of participants) | 20 (71%) | 8 (32%) | 48 (29%) | < .001 |
| Variable . | Vector based, n = 28∗ . | Only 1†, n = 25∗ . | 2× mRNA-based, n = 168∗ . | P value‡ . |
|---|---|---|---|---|
| Age (y) | 53 (45; 60) | 55 (48; 61) | 60 (47; 69) | .05 |
| Sex | .2 | |||
| Female | 13 (46%) | 8 (32%) | 87 (52%) | |
| Male | 15 (54%) | 17 (68%) | 81 (48%) | |
| WBC | 5.5 (4.5; 6.1) | 5.7 (4.7; 7.1) | 6.3 (4.8; 8.2) | .1 |
| Study cohort | .07 | |||
| Healthy control | 13 (46%) | 16 (64%) | 62 (37%) | |
| Lymphoid neoplasms | 4 (14%) | 1 (4%) | 37 (22%) | |
| Myeloid neoplasms | 11 (39%) | 8 (32%) | 69 (41%) | |
| Prior SARS-CoV-2 infection | < .001 | |||
| Yes | 0 (0%) | 7 (28%) | 2 (1.2%) | |
| No | 28 (100%) | 18 (72%) | 166 (98.8%) | |
| Current cancer treatment | .4 | |||
| Yes | 11 (39%) | 6 (24%) | 64 (38%) | |
| No | 17 (61%) | 19 (76%) | 104 (62%) | |
| Spike-specific IgG detectable (n [%] of participants) | 26 (93%) | 23 (96%) | 159 (95%) | .9 |
| Spike-specific CD4+ T cells detectable (n [%] of participants) | 27 (96%) | 15 (60%) | 102 (61%) | .001 |
| Spike-specific CD8+ T cells detectable (n (%) of participants) | 20 (71%) | 8 (32%) | 48 (29%) | < .001 |
Vaccination success is expressed as percentage of study participants with detectable spike-specific IgG, CD4+, and CD8+ responses, respectively. WBC, white blood cell count.
Significant (<0.05) P values are highlighted in bold.
Median (Q1 and Q3); n (%).
Summarizes in-label Ad26.COV2.S (Janssen) and off-label single-shot immunization using either mRNA vaccine.
Kruskal-Wallis rank sum test; Fisher exact test.